<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736472</url>
  </required_header>
  <id_info>
    <org_study_id>844763</org_study_id>
    <nct_id>NCT04736472</nct_id>
  </id_info>
  <brief_title>Implementing Pharmacogenetic Testing in Gastrointestinal Cancers</brief_title>
  <acronym>IMPACT-GI</acronym>
  <official_title>Implementing Pharmacogenetic Testing in Gastrointestinal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx&#xD;
      testing for certain genes can help predict the risk of side effects from chemotherapy agents.&#xD;
      Testing is not regularly performed in clinical practice due to long wait times for results&#xD;
      and challenges with integrating test results in the electronic health record. Investigators&#xD;
      leading this study hope to find out if providing cancer care providers with the ability to&#xD;
      order a PGx test and electronically receive results with dosing recommendations will increase&#xD;
      the use of these tests to guide treatment decisions and improve patient outcomes.&#xD;
&#xD;
      This is a non-randomized implementation study, which means that all participants in this&#xD;
      study will undergo genotyping for a pharmacogenetic test. The investigators will primarily&#xD;
      measure the feasibility of using this test to guide cancer care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a nonrandomized, open-label study to investigate the feasibility of establishing and integrating a pharmacogenetic test into clinical oncology care. A historical control group of patients with gastrointestinal cancers enrolled in a biobank will be used to compare toxicity outcomes of the prospectively-genotyped patients.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility: proportion of pharmacogenetic tests returned prior to initial dose</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of pharmacogenetic tests returned prior to the first determined dose of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fidelity: level of agreement with dose recommendations</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of dose modifications made in agreement with the genotype-guided dosing recommendations for the first dose of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penetrance: proportion of pharmacogenetic tests ordered by providers</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of pharmacogenetic tests ordered compared to the number of patient with eligible for testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or higher toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients experiencing grade 3 or higher chemotherapy induced toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>DPYD/UGT1A1 pharmacogenetic testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be screened for twelve single nucleotide polymorphisms (SNPs) in DPYD: DPYD*2A, *5, *6, *8, *9A, *10, *12, *13, rs2297595, rs115232898, rs67376798, HapB3.&#xD;
All patients will be screened for two SNPs in UGT1A1: UGT1A1*6, *28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pharmacogenetic test</intervention_name>
    <description>Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.</description>
    <arm_group_label>DPYD/UGT1A1 pharmacogenetic testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide informed consent&#xD;
&#xD;
          2. Male or female, aged 18 years or older at the time of study initiation&#xD;
&#xD;
          3. Pathologically confirmed gastrointestinal malignancy for which treatment with a&#xD;
             fluoropyrimidine and/or irinotecan is indicated&#xD;
&#xD;
          4. Willing to undergo blood sampling for PGx testing and comply with all study-related&#xD;
             procedures&#xD;
&#xD;
          5. Life expectancy of at least 6 months&#xD;
&#xD;
          6. ECOG performance status of 0, 1 or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with fluoropyrimidines and/or irinotecan&#xD;
&#xD;
          2. DPYD or UGT1A1 genotype already known&#xD;
&#xD;
          3. Severe renal or hepatic impairment (or unacceptable laboratory values), including:&#xD;
&#xD;
               -  Neutrophil count of &lt;1.5 x 109/L, platelet count of &lt;100 x 109/L&#xD;
&#xD;
               -  Hepatic function as defined by serum bilirubin &gt;1.5 x upper limit of normal&#xD;
                  (ULN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) &gt;2.5&#xD;
                  x ULN, or in case of liver metastases ALT and AST&gt;5 x ULN&#xD;
&#xD;
               -  Renal function as defined by serum creatinine &gt;1.5 x ULN, or creatinine clearance&#xD;
                  &lt;60 ml/min (by Cockcroft-Gault Equation)&#xD;
&#xD;
          4. Women who are pregnant or breast feeding, or subjects who refuse to use reliable&#xD;
             contraceptive methods throughout the study&#xD;
&#xD;
          5. Treating physician does not want subject to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sony Tuteja, PharmD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Perelman School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sony Tuteja, PharmD, MS</last_name>
    <phone>215-573-7834</phone>
    <email>sonyt@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Varughese, PharmD</last_name>
    <phone>215-662-7194</phone>
    <email>lisa.varughese@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Varughese, PharmD</last_name>
      <email>lisa.varughese@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Sony Tuteja, PharmD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ursina Teitelbaum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Varughese, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Sony Tuteja</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Fluoropyrimidines</keyword>
  <keyword>Topoisomerase I inhibitors</keyword>
  <keyword>Antimetabolites, Antineoplastics</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Study protocol, SAP, ICF will be made available 1 year following enrollment of the last participant. IPD will be made available 6 months after publication of study results.</ipd_time_frame>
    <ipd_access_criteria>Contact PI, Sony Tuteja, PharmD, sonyt@pennmedicine.upenn.edu with individual requests.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

